Passions

Creative writing

Music

Reading

Admissions and credentials

New York

Experience

Sirius Therapeutics Announces Collaboration With CRISPR Therapeutics

May 19, 2025

Cooley advised Sirius Therapeutics, a clinical-stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, on its strategic partnership to develop and commercialize siRNA therapies with CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Jiqiang Lin
Associate, New York
Navya Dasari
Associate, New York
Aaron Pomeroy
Partner, Colorado
Todd Gluth
Partner, San Diego
Rick Jantz
Associate, Santa Monica
Steve Przesmicki
Partner, San Diego
Robert Eisenbach
Of Counsel, San Francisco
Rachel Thorn
Of counsel, New York
David Burns
Special Counsel, Washington, DC
Eileen Marshall
Partner, Washington, DC
Jonathan Rivinus
Partner, Colorado

Related Practices & Industries

Jiangsu Hengrui Pharmaceuticals Announces License Agreement With Merck

March 25, 2025

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck (NYSE: MRK), known as MSD outside of the US and Canada, for HRS-5346, an investigational oral small molecule lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a phase 2 clinical trial in China.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Jiqiang Lin
Associate, New York
Andrew Epstein
Special Counsel, Seattle
Zhijing Yu
Associate, Singapore
David Burns
Special Counsel, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
Navya Dasari
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Russell Anderson
Partner, London
Megan Browdie
Partner, Washington, DC
Steve Przesmicki
Partner, San Diego

Related Practices & Industries

Alumis Announces Merger With ACELYRIN

February 6, 2025

Cooley advised Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, on its definitive agreement with ACELYRIN to merge in an all-stock transaction.

Read more

Related contacts

Jamie Leigh
Partner, San Francisco
David Peinsipp
Partner, San Francisco
Ben Beerle
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Polina A. Demina
Special Counsel, New York
Sangitha Palaniappa
Associate, Palo Alto
Christine Turner
Associate, Colorado
Shaun (Tianjie) Wang
Associate, New York
Megan Browdie
Partner, Washington, DC
Lauren Creel
Partner, Palo Alto
Ross Eberly
Partner, Santa Monica
Stephanie Gentile
Partner, New York
Sarah Lightdale
Partner, New York
Phil Mitchell
Partner, New York
Jeremy Morrison
Partner, Washington, DC
Alessandra Murata
Partner, Palo Alto
Jennifer Raab
Partner, Palo Alto
Patrick Van Eecke
Partner, Brussels
Natasha Leskovsek
Of Counsel, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Caroline Vu
Special Counsel, Palo Alto
Christopher Andrews
Associate, New York
Dannielle Antone
Associate, San Francisco
Tamara Chin Loy
Associate, Washington, DC
Navya Dasari
Associate, New York
Joshua Elefant
Associate, Palo Alto
Winda Fung
Associate, Santa Monica
Gary Warren Hunt III
Associate, Washington, DC
Wyatt Kernell
Associate, Colorado
Kristina Krasnikova
Associate, Palo Alto
Sunny J. Levine
Associate, Colorado
Amanda Lindner
Associate, New York
Jayne M. Munger
Associate, New York
Julianne Orr
Associate, San Francisco
Michael Pelle
Associate, New York
Breanna Qin
Associate, Palo Alto
Bartholomäus Regenhardt
Associate, Brussels
Jesse Schulman
Associate, Colorado
Freddy Yip
Associate, Hong Kong
Isabella Ysebrands
Associate, San Francisco

Related Practices & Industries

Tvardi Therapeutics Announces Merger With Cara Therapeutics

December 18, 2024

 

Cooley advised Tvardi Therapeutics, a privately held, clinical-stage biopharmaceutical company focused on the development of novel, oral, small-molecule therapies targeting STAT3 to treat fibrosis-driven diseases, on its definitive merger agreement to combine in an all-stock transaction with Cara Therapeutics (Nasdaq: CARA), a development-stage biopharmaceutical company that has been leading a new treatment paradigm to improve the lives of patients suffering from pruritus.

Read more

Related contacts

Div Gupta
Partner, New York
Rama Padmanabhan
Partner, San Diego
Carlos Ramirez
Partner, San Diego
Lindsey O'Crump
Associate, Washington, DC
Brittany K. Wightman
Associate, San Diego
Michael Bergmann
Partner, Washington, DC
Ross Eberly
Partner, Santa Monica
Lila Hope
Partner, Palo Alto
Xander Lee
Partner, Santa Monica
Phil Mitchell
Partner, New York
Howard Morse
Senior Counsel, Washington, DC
Francis Wheeler
Senior Counsel, Colorado
Natasha Leskovsek
Of Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Reid Hooper
Special Counsel, Washington, DC
Justin Kisner
Special Counsel, Palo Alto
Dani Nazemian
Special Counsel, San Diego
Stella Sarma
Partner, Brussels
Karen Tsai
Special Counsel, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
Navya Dasari
Associate, New York
Jeremy Gentile
Associate, San Diego
Carly E. Gibbons
Associate, Chicago
Wyatt Kernell
Associate, Colorado
Jiqiang Lin
Associate, New York
Kelly McCormick
Associate, San Francisco
Jonathan Perez-Reyzin
Associate, San Diego
Carly Robinson
Associate, Reston
Jesse Schulman
Associate, Colorado
Rebecca Siegel
Associate, San Francisco
Tania Soris
Associate, New York
Patricia Myers
Paralegal Specialist, Colorado
Jake Ironfield
Transactional Quantitative Analyst, New York
Brian Mitchell
Transactional Quantitative Analyst, San Diego

Related Practices & Industries

Keros Therapeutics Announces Ex-China Global License Agreement With Takeda

December 3, 2024

Cooley advised Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, on its exclusive global development and commercialization license agreement with Takeda Pharmaceuticals to advance elritercept.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Ryan Sansom
Partner, Boston
Marc Recht
Partner, Boston
David Burns
Special Counsel, Washington, DC
Navya Dasari
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Bartholomäus Regenhardt
Associate, Brussels
Stella Sarma
Partner, Brussels

Related Practices & Industries

Memberships and affiliations

American Bar Association (ABA)